The Global Market for Mesenchymal Stem Cells (MSCs) is Projected to Exceed US$7.2 Billion by 2022

Ability to Provide Targeted Delivery of Therapeutics to Drive the Global Mesenchymal Stem Cells Market, According to a New Report by Global Industry Analysts, Inc.

GIA launches comprehensive analysis of industry segments, trends, growth drivers, market share, size and demand forecasts on the global Mesenchymal Stem Cells (MSCs) market. The global market for Mesenchymal Stem Cells (MSCs) is projected to exceed US$7.2 billion by 2022, driven by the rapidly aging population, rising incidence of chronic diseases, government support in the form of favorable regulations and funding, and increasing investments in stem cell-biology.

Mesenchymal Stem Cells (MSCs) are gradually gaining therapeutic interest as they are increasingly considered to have the potential to treat various degenerative and acute diseases. MSCs are mainly used for replacing or repairing damaged tissues. Application of MSCs in various therapeutic areas is largely due to the cells’ ability to differentiate into a broad array of cells, and also due to their localization properties. The cells have the ability to easily migrate to tissue injury or tumor sites which helps in targeted delivery of therapeutic medication. Therapeutic agents can be introduced precisely at the target sites with the help of MSC gene therapies. MSCs have the potential to be used for releasing bioactive molecules to stimulate recovery of injured cells. MSCs are additionally known for their robust immunosuppressive properties because of which, they are expected to be further exploited by researchers for developing heterologous as well as autologous therapies for various diseases in the near future. The growth in the market is benefiting from the rapidly aging population, rising incidence of chronic diseases, government support in the form of favorable regulations and funding, and rising investments in the area of stem cell-biology. MSCs are also being increasingly used for substituting operative procedures such as knee-replacement surgeries. Collaborations and partnerships, and increased emphasis on innovation constitute the key trends in the market. There is also a growing interest in conducting further research on MSCs for exploring their potential in tissue engineering as well as cellular therapy.

As stated by the new market research report on Mesenchymal Stem Cells, the United States represents the largest market worldwide. Asia-Pacific ranks as the fastest growing market led by India and China. Large pool of patients who can be treated with MSC therapies; increasing governmental support and funding for popularizing MSC therapies as part of larger healthcare improvement strategies; developing healthcare infrastructure; growing GDP, rising living standards and higher healthcare spending represent major factors driving growth in China and India.    

Key players covered in the report include Vericel Corporation, Cell Applications Inc., Celprogen Inc., Cyagen Biosciences Inc., MilliporeSigma, Genlantis Inc, Thermo Fischer Scientific Inc., Lonza Group, Mesoblast Limited, Neuromics, Orthofix International N.V, PromoCell GmbH., R&D Systems Inc., ScienCell Research Laboratories, Stemcell Technologies Inc., Stemedica Cell Technologies Inc. Trevigen Inc., and Vitro Biopharma, among others.

The research report titled "Mesenchymal Stem Cells (MSCs): A Global Strategic Business Report" announced by Global Industry Analysts Inc., provides a comprehensive review of the market, industry overview, trends, growth drivers, latest product launches and recent industry activity. The report provides market estimates and projections in US dollars for major geographic markets including the United States, Canada, Japan, Europe, Asia-Pacific, and Rest of World.

Global Industry Analysts, Inc. 6150 Hellyer Ave., San Jose CA 95138, USA, All Rights Reserved.